Shorter venetoclax durations in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) yielded ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

AbbVie ABBV announced that the phase III VERONA study failed to meet the primary endpoint of overall survival. The study ...

AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival. The drugmaker ...

The AbbVie-Roche cancer drug venetoclax failed to meet its primary endpoint in a phase 3 trial to treat newly diagnosed ...

The VERONA trial evaluated the safety and efficacy of venetoclax with azacitidine in treatment-naïve adults with higher-risk MDS.

AbbVie (ABBV) said on Monday that its late-stage trial evaluating its drug Venetoclax in combination with Azacitidine in the ...

AbbVie (ABBV) announced the global Phase 3 Vevrona trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome did not meet the ...

Roche and AbbVie have once again come up short in their attempt to gain an additional indication for their blockbuster blood ...

(RTTNews) - AbbVie Inc. (ABBV) Monday said its Phase 3 VERONA study evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome ...

AbbVie is deploying more capital into its pipeline, which features 50 programs in mid- and late-stage development and over ...

AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival. The ...